Suppliers to the biopharmaceutical and life science industries are collaborating to jointly drive the go to market and scale-up of cultured meat based on their experience in areas such as bioprocess development, quality control and regulatory compliance.

The company's biology team has reduced the cost of its in-house growth media for bovine cell cultivation in suspension by just over 75% from prices two years ago.

"Canadian Foodtech Trends: Interest and Curiosity in Cellular Food Continues to Grow" is the first of its kind report on the Canadian cellular food industry.

This expands the company’s line of cultured meat for the pet food market.

The company will use the fresh money to drive regulatory approval of its first products, expanding research work and initiating pilot production.

The insulin substituents can reduce the cost and development time for producing cultivated meat at scale.

The new product is a result of the company's recently filed patent for 3D-bioprinting technology which allows high levels of marbling control within a consolidated structure.